ReviewHuman reproduction (Oxford, England)2025
Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies.
Review in Human reproduction (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.Journal of the National Cancer Institute · 2025Trial
- Advances in the application of assisted reproductive technology in fertility preservation for female patients with malignant tumours of the reproductive systems.Annals of medicine · 2026Review
- Fertility in breast cancer survivorship: a scoping review.Journal of cancer survivorship : research and practice · 2026Review
- Fertility treatment using assisted reproductive technology during immune checkpoint inhibition: report of two cases.The oncologist · 2026Article
- Fertility preservation in prepubertal boys: management and follow-up challenges.Endocrine connections · 2026Review
- Oncofertility outcomes in early-onset patients with non-breast solid malignancies: a systematic review.EClinicalMedicine · 2026Article
- IVF outcomes in cancer survivors: lower ovarian response and early embryo development but comparable success in frozen embryo transfer cycles - a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Fertility preservation and reproductive outcomes in young women with breast and gynecological cancers: a new challenge for the clinician.Frontiers in oncology · 2026Review
- The dual nature of immunotherapy in female reproductive disorders: immune homeostasis and clinical challenges.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In recent years, cancer treatment has been revolutionized by the introduction of many novel drugs, including immunotherapy and targeted agents, which have significantly improved the prognosis of patients with different solid tumors. While the role of traditional cytotoxic agents on fertility and reproductive health of patients with cancer is currently well established, the impact of novel treatments remains an unmet medical need and a subject of concern. Limited clinical evidence exists to date on the potential gonadotoxicity of targeted agents and immunotherapy. However, in preclinical male and female animal models, several new treatments have demonstrated the potential to affect reproductive capacity. Hence, the possible impact of these treatments on patients' reproductive potential should be urgently addressed. This work aims to review the most recent evidence regarding the gonadotoxicity of immunotherapy and novel targeted agents from the mechanisms of action of these treatments to the preclinical and clinical available data, as well as the implications on chances and risks of subsequent pregnancies. The final aim is to provide a useful tool to both physicians and patients for an informed decision-making process regarding fertility preservation and family planning before and after exposure to the new anticancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.